|
Volumn 53, Issue 3, 2001, Pages 409-412
|
Effect of indinavir on the pharmacokinetics of rifampicin in HIV-infected patients
a a |
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIRETROVIRUS AGENT;
CYTOCHROME P450;
INDINAVIR;
RIFAMPICIN;
ADULT;
AREA UNDER THE CURVE;
ARTICLE;
CLINICAL ARTICLE;
CLINICAL TRIAL;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
DRUG BLOOD LEVEL;
DRUG EFFECT;
DRUG INHIBITION;
DRUG METABOLISM;
EPIDEMIC;
FEMALE;
HUMAN;
HUMAN IMMUNODEFICIENCY VIRUS;
HUMAN IMMUNODEFICIENCY VIRUS INFECTION;
INCIDENCE;
MALE;
MAXIMUM ALLOWABLE CONCENTRATION;
MONOTHERAPY;
PHASE 1 CLINICAL TRIAL;
PHASE 2 CLINICAL TRIAL;
TUBERCULOSIS;
ADULT;
ANTI-HIV AGENTS;
ANTIBIOTICS, ANTITUBERCULAR;
AREA UNDER CURVE;
DRUG INTERACTIONS;
FEMALE;
HIV INFECTIONS;
HUMANS;
INDINAVIR;
MALE;
MIDDLE AGED;
RIFAMPIN;
|
EID: 0035095725
PISSN: 00223573
EISSN: None
Source Type: Journal
DOI: 10.1211/0022357011775488 Document Type: Article |
Times cited : (9)
|
References (9)
|